"Merck said it would continue to develop its two experimental Covid-19 therapeutics. Full results from a Phase 3 study of one of the drugs, called MK-7110, are expected this quarter. A Phase 2/3 study of the other drug, an antiviral called molnupiravir that Merck is developing in collaboration with a privately-held firm called Ridgeback"
"Merck said it would continue to develop its two experimental Covid-19 therapeutics. Full results from a Phase 3 study of one of the drugs, called MK-7110, are expected this quarter. A Phase 2/3 study of the other drug, an antiviral called molnupiravir that Merck is developing in collaboration with a privately-held firm called Ridgeback"